# Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer

> **NCT00920192** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 45 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Foretinib

## Key facts

- **NCT ID:** NCT00920192
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-12
- **Primary completion:** 2012-03-07
- **Final completion:** 2015-03-24
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920192, "Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00920192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*